Ivan Coulter

Ivan Coulter is an experienced entrepreneur, C-level executive, board member, and innovator based in Ireland.1 He is currently the Co-Founder of Inthelia Therapeutics, a company he established in June 2020 that focuses on fighting blood-borne infections by targeting a common host target rather than a pathogen target.1

Professional Background

Coulter has an extensive career in the biopharmaceutical and healthcare industries:

Current Roles::

• Co-Founder of Inthelia Therapeutics (since June 2020)
• Founder & Managing Director of Eden BioPharma Limited (since January 2020)

Previous Positions::

• Chief Technology Officer at Sublimity Therapeutics (May 2018 - September 2018)
• Founder, CEO, and CTO of Sigmoid Pharma Limited (August 2003 - May 2018)
• Board Member of BIM (Bord Iascaigh Mhara), the Irish State agency for sea fishing and aquaculture industries (July 2007 - August 2011)
• General Manager at NTera Limited (April 2000 - September 2003)

Education

Coulter has a strong educational background:

• Post-Doctoral research in Developmental Biology at Institut Curie (1996-2000)
• MBA in Business from Cornell University (1999-2000)
• Diploma in Corporate Governance from The Corporate Governance Institute (2020-2021)
• CDipAF in Accountancy and Finance from ACCA (1992-1993)1

Expertise and Focus

Ivan Coulter is known for his expertise in:

• Translating early-stage innovations into clinical development programs
• Developing novel therapeutics, particularly in areas like inflammatory bowel disease and autoimmune conditions
• Leveraging technology platforms for drug delivery and development1

His current work with Inthelia Therapeutics and Eden BioPharma demonstrates his ongoing commitment to innovation in healthcare and biopharmaceuticals, with a particular focus on developing high-value products that have the potential to improve patients' lives.1